Literature DB >> 26081009

Analysis of dystrophin gene in Iranian Duchenne and Becker muscular dystrophies patients and identification of a novel mutation.

Gholam Reza Zamani1,2, Fatemeh Karami3, Mahshid Mehdizadeh4, Abolfazl Movafagh5, Yalda Nilipour6, Mahdi Zamani7,8.   

Abstract

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most frequent muscular dystrophies. Present study aimed to determine the frequency of dystrophin gene alterations in Iranian DMD/BMD patients using molecular techniques. 146 Iranian DMD/BMD patients have been analyzed using two devised sets of multiplex polymerase chain reaction (M-PCR) followed by multiple ligation-dependent probe amplification (MLPA). Two isolated DMD and BMD patients were analyzed by DNA sequencing. 30.9 % of patients had single-exon deletion while group and contiguous exon deletions were identified in 41 % of the patients. The most numerous exon deletions included exons 45-50 and were identified in the first M-PCR set. Deletion detection rate was 99 % in first M-PCR set and remaining deletions (1 %) were identified in the second M-PCR set. MLPA analysis showed that there were two exons 3-5 and 41-43 duplications (1.4 %) in a BMD and a DMD patient, respectively. Two nonsense mutations including c.633dupA and c.6283 C>T were, respectively, found in a DMD and BMD patient in which c.633dupA has not ever been reported in DMD mutation database and was pathogenic mutation. Besides the report of frequency of dystrophin gene alteration in a subset of Iranian DMD/BMD patients, it was revealed that the proposed M-PCR protocol can be useful in the initial step of molecular diagnosis of DMD/BMD. Exon sequencing would be the final step in determining the mutation status of DMD/BMD patients following MLPA.

Entities:  

Keywords:  BMD; DMD; MLPA; Multiplex PCR; Mutation

Mesh:

Substances:

Year:  2015        PMID: 26081009     DOI: 10.1007/s10072-015-2290-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

1.  Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families.

Authors:  M A Melis; M Cau; F Muntoni; A Mateddu; R Galanello; L Boccone; F Deidda; D Loi; A Cao
Journal:  Eur J Paediatr Neurol       Date:  1998       Impact factor: 3.140

2.  Strategy for comprehensive molecular testing for Duchenne and Becker muscular dystrophies.

Authors:  Tracy L Stockley; Sarah Akber; Natalie Bulgin; Peter N Ray
Journal:  Genet Test       Date:  2006

3.  Dystrophin gene mutation analysis in Iranian males and females using multiplex polymerase chain reaction and multiplex ligation-dependent probe amplification methods.

Authors:  Faravareh Khordadpoor-Deilamani; Mohammad Taghi Akbari; Shahriar Nafissi; Gholamreza Zamani
Journal:  Genet Test Mol Biomarkers       Date:  2011-08-04

4.  Genetic diagnosis of Duchenne and Becker muscular dystrophy using next-generation sequencing technology: comprehensive mutational search in a single platform.

Authors:  Byung Chan Lim; Seungbok Lee; Jong-Yeon Shin; Jong-Il Kim; Hee Hwang; Ki Joong Kim; Yong Seung Hwang; Jeong-Sun Seo; Jong Hee Chae
Journal:  J Med Genet       Date:  2011-10-03       Impact factor: 6.318

5.  Detection of Duchenne/Becker muscular dystrophy carriers in a group of Iranian families by linkage analysis.

Authors:  Fardeen Ali Malayeri; Mojtaba Panjehpour; Ahmad Movahedian; Majid Ghaffarpour; Gholam Reza Zamani; Mina Hajifaraj Tabrizi; Mahdi Zamani
Journal:  Acta Med Iran       Date:  2011

6.  A missense mutation in the dystrophin gene in a Duchenne muscular dystrophy patient.

Authors:  T W Prior; A C Papp; P J Snyder; A H Burghes; C Bartolo; M S Sedra; L M Western; J R Mendell
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

7.  [Combining approach with multiplex PCR and MLPA to detect deletion and duplication in DMD patients, carriers, and prenatal diagnosis].

Authors:  Hong Li; Jie Ding; Wei Wang; Ying Chen; Wei Lu; Hong Shao; Bai-lin Wu
Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi       Date:  2009-06

8.  Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification.

Authors:  J S Chamberlain; R A Gibbs; J E Ranier; P N Nguyen; C T Caskey
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

9.  Genetic analysis of dystrophin gene for affected male and female carriers with Duchenne/Becker muscular dystrophy in Korea.

Authors:  Bo Lyun Lee; Sook Hyun Nam; Jun Hwa Lee; Chang Seok Ki; Munhyang Lee; Jeehun Lee
Journal:  J Korean Med Sci       Date:  2012-02-23       Impact factor: 2.153

10.  A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.

Authors:  Gemma L Walmsley; Virginia Arechavala-Gomeza; Marta Fernandez-Fuente; Margaret M Burke; Nicole Nagel; Angela Holder; Rachael Stanley; Kate Chandler; Stanley L Marks; Francesco Muntoni; G Diane Shelton; Richard J Piercy
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more
  3 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

2.  Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.

Authors:  Gholamreza Zamani; Sareh Hosseinpour; Mahmoud Reza Ashrafi; Mahmoud Mohammadi; Reza Shervin Badv; Ali Reza Tavasoli; Masood Ghahvechi Akbari; Ali Hosseini Bereshneh; Reza Azizi Malamiri; Morteza Heidari
Journal:  BMC Neurol       Date:  2022-05-02       Impact factor: 2.903

3.  Novel Exon-Skipping Therapeutic Approach for the DMD Gene Based on Asymptomatic Deletions of Exon 49.

Authors:  Mario Abaji; Svetlana Gorokhova; Nathalie Da Silva; Tiffany Busa; Maude Grelet; Chantal Missirian; Sabine Sigaudy; Nicole Philip; France Leturcq; Nicolas Lévy; Martin Krahn; Marc Bartoli
Journal:  Genes (Basel)       Date:  2022-07-19       Impact factor: 4.141

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.